Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cavosonstat Phase 1b in CF
NCT02275936Phase 1Completed
- Sponsor
- Nivalis Therapeutics
- Start
- Feb 2015
- Primary completion
- Jul 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of cavosonstat in cystic fibrosis (CF) (4 arms), sponsored by Nivalis Therapeutics. Primary endpoint: Safety assessments based on clinical evaluations, laboratory assessments, and adverse events at 28 Days. Started Feb 2015; status: completed.
02
Drugs
cavosonstat
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT02275936.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02275936.